Vitro Biopharma is an innovative biotechnology company with a mission to develop Wharton's jelly-derived cell therapies for autoimmune diseases and inflammatory disorders. With a focus on translating scientific advancements into transformative medicines, their goal is to become a leader in the immunology and inflammatory market. The company's pipeline includes differentiated product candidates that have been developed in a rapid and efficient manner, aiming to meet the needs of patients with various diseases.

They prioritize quality manufacturing, adhering to strict environmental and laboratory controls in compliance with cGMP regulations. Their scalable and standardized manufacturing process, which leverages the biological advantages of UC-derived MSCs, gives them a significant cost and competitive advantage over their peers. Vitro Biopharma keeps their stakeholders informed through their newsroom, powered by cutting-edge biotechnology.

They are committed to privacy, follow a comprehensive privacy policy, and provide a transparent and fulfilling work environment for their employees. With a dedication to advancing healthcare, Vitro Biopharma is poised to make a lasting impact in the biopharmaceutical industry